A pharmaceutical company sought to lead efforts in understanding Mexico’s healthcare landscape for Syncytial Respiratory Virus (SRV), especially to improve infant care. Speyside organized a focus group with medical experts and civil society, using stakeholder mapping and support materials to gather insights. The result was a final report with public policy recommendations. These insights helped the company understand challenges in the public healthcare system and provided a clear foundation for future advocacy and engagement with decision-makers.

A renowned pharmaceutical company aimed to take the lead in understanding Mexico’s healthcare landscape for Syncytial Respiratory Virus (SRV), identifying both challenges and opportunities, and developing public policy recommendations to improve treatment—particularly for infants. This required bringing together diverse perspectives from the medical community and civil society to inform a robust, context-specific policy agenda.

Speyside designed and executed a targeted focus group in Mexico, engaging medical experts and a civil society organization specializing in SRV and infant care within the national healthcare system. The process included stakeholder mapping to identify and prioritize participants, securing their commitment, preparing supporting materials, and ensuring high value input. Speyside then consolidated the group’s input into a final report with key insights and actionable public policy recommendations.

The focus group provided the company with valuable, first-hand insights into SRV treatment  challenges in Mexico, particularly within its public healthcare system. Physicians shared their perspectives on the use and positioning of the company’s treatment, offering practical guidance for clinical adoption. In addition, participants proposed concrete public policy recommendations to strengthen SRV care, equipping the company with a clear, evidence-based foundation for advocacy and engagement with decision-makers.